Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Claudia Caserta"'
Autor:
Maria Letizia Calandrella, Simona Francesconi, Cecilia Caprera, Claudia Mosillo, Claudia Caserta, Diana Giannarelli, Matteo Corsi, Serena Macrini, Annalisa Guida, Stefano Ascani, Sergio Bracarda
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-7 (2022)
Abstract Background Upper urinary tract urothelial carcinoma (UTUC) accounts for only about 5–10% of all urothelial cancers and is characterized by an aggressive and frequently rapidly fatal behavior. However, detailed knowledge of its molecular pr
Externí odkaz:
https://doaj.org/article/3941fb50bc194a1397376e4072713bb0
Autor:
Claudia Mosillo, Maria Letizia Calandrella, Claudia Caserta, Serena Macrini, Annalisa Guida, Grazia Sirgiovanni, Sergio Bracarda
Publikováno v:
Cancers, Vol 14, Iss 17, p 4189 (2022)
Prostate cancer is the second most common diagnosed cancer and the fifth leading cause of cancer-related deaths in men worldwide. Despite significant advances in the management of castration-sensitive prostate cancer, the majority of patients develop
Externí odkaz:
https://doaj.org/article/d6cb4ff5592b4c1aa9d1cac7263d9b46
Autor:
Serena Macrini, Simona Francesconi, Cecilia Caprera, Daniela Lancia, Matteo Corsi, Marco Gunnellini, Andrea Rocchi, Anjuta Pireddu, Fiovo Marziani, Claudia Mosillo, Maria Letizia Calandrella, Claudia Caserta, Diana Giannarelli, Annalisa Guida, Stefano Ascani, Sergio Bracarda
Publikováno v:
Cancers, Vol 14, Iss 6, p 1542 (2022)
The recurrent genetic anomalies used to classify prostate cancer (PC) into distinct molecular subtypes have limited relevance for clinical practice. In consideration of WHO 2016 histological classification, which includes the introduction of Gleason
Externí odkaz:
https://doaj.org/article/4ed32db67ff94003a5ec79bd2a68b414
Autor:
Marta Padovan, Marica Eoli, Alessia Pellerino, Simona Rizzato, Claudia Caserta, Matteo Simonelli, Maria Michiara, Mario Caccese, Elena Anghileri, Giulia Cerretti, Roberta Rudà, Vittorina Zagonel, Giuseppe Lombardi
Publikováno v:
Cancers, Vol 13, Iss 11, p 2773 (2021)
Background: Depatuxizumab Mafodotin (Depatux-M; ABT-414) is an antibody-drug conjugate consisting of a specific antibody against activated EGFR and a cytotoxic agent with antimicrotubule activity. The INTELLANCE 2/EORTC 1410 phase 2 trial produced in
Externí odkaz:
https://doaj.org/article/8d8d7ef723c141458cf9906f85615854
Autor:
Maria Giuseppa Vitale, Sarah Scagliarini, Luca Galli, Sandro Pignata, Giovanni Lo Re, Alfredo Berruti, Carlotta Defferrari, Massimiliano Spada, Cristina Masini, Daniele Santini, Libero Ciuffreda, Enzo Maria Ruggeri, Carmelo Bengala, Lorenzo Livi, Daniele Fagnani, Andrea Bonetti, Lucio Giustini, Alketa Hamzaj, Giuseppe Procopio, Claudia Caserta, Roberto Sabbatini
Publikováno v:
PLoS ONE, Vol 13, Iss 7, p e0199642 (2018)
BACKGROUND:Results from phase III clinical trial CheckMate 025 have established nivolumab as the standard of care for treatment of metastatic renal-cell carcinoma (mRCC) after VEGF inhibitor failure; however, elderly patients are under-represented in
Externí odkaz:
https://doaj.org/article/d4bd7db75d9e42c5aea3c56d4c5c054a
Autor:
Thomas Powles, Se Hoon Park, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon-Ching, Jing Wang, Bo Huang, Robert J. Laliberte, Alessandra di Pietro, Petros Grivas
Publikováno v:
Journal of Clinical Oncology.
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical tri
Autor:
Begoña Valderrama, Thomas Powles, Srikala Sridhar, Claudia Caserta, Yohann Loriot, Shilpa Gupta, Joaquim Bellmunt, Cora Sternberg, Jing Wang, Nuno Costa, Robert Laliberte, Alessandra di Pietro, Se Hoon Park, Petros Grivas
Publikováno v:
Journal of Urology. 209
Autor:
Petros Grivas, Se Hoon Park, Eric Voog, Claudia Caserta, Howard Gurney, Joaquim Bellmunt, Haralabos Kalofonos, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Yoshiaki Yamamoto, Daniel P. Petrylak, Cora N. Sternberg, Shilpa Gupta, Bo Huang, Nuno Costa, Robert J. Laliberte, Alessandra di Pietro, Begoña P. Valderrama, Thomas Powles
Publikováno v:
European Urology.
Autor:
Orazio Caffo, Giacomo Cartenì, Sebastiano Buti, Melissa Bersanelli, Elena Fea, Umberto Basso, Francesco Massari, Francesco Boccardo, Alfredo Berruti, Fausto Petrelli, Roberto Iacovelli, Gaetano Facchini, Luca Galli, Alessandra Mosca, Gaetano Aurilio, Claudia Caserta, Ugo De Giorgi, Giuseppe Fornarini, Giuseppe Procopio, Camillo Porta, Emanuele Naglieri
Publikováno v:
World Journal of Clinical Oncology
BACKGROUND Non-clear cell (ncc) metastatic renal-cell carcinoma (RCC) has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart. New systemic combination therapies have emerged for
Autor:
Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong-Seok Lee, Justin F. Gainor, Gregory A. Otterson, Clarisse Audigier-Valette, Neal Ready, Michael Schenker, Helena Linardou, Reyes Bernabe Caro, Mariano Provencio, Bogdan Zurawski, Ki Hyeong Lee, Sang-We Kim, Claudia Caserta, Suresh S. Ramalingam, David R. Spigel, Julie R. Brahmer, Martin Reck, Kenneth J. O’Byrne, Nicolas Girard, Sanjay Popat, Solange Peters, Arteid Memaj, Faith Nathan, Nivedita Aanur, Hossein Borghaei
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 18(1)
We characterized the safety of first-line nivolumab plus ipilimumab (NIVO+IPI) in a large patient population with metastatic NSCLC and efficacy outcomes after NIVO+IPI discontinuation owing to treatment-related adverse events (TRAEs).We pooled data f